Regent Pacific's Premature Ejaculation Treatment PSD502® Enters Final Stage of Commercialisation

- Reduced fill can approval to trigger €6 million payment from commercial partner Recordati
- Full commercial launch in Europe expected H2 2016; up to €10 million in total to be received from Recordati as sales commence

(18 April 2016, Hong Kong) – **Regent Pacific Group Limited** ("Regent Pacific" or "the Group"; stock code: 00575), a healthcare and life sciences investment group, announces today that it has received acceptable stability data for a reduced fill can version of PSD502®, a prescription treatment for premature ejaculation. The positive results of the testing by Catalent, which assessed the storage performance of the product under various types of environmental conditions, mean that the Group will now make a Type Ib variation submission to the European Medicines Agency ("EMA") by 20 April 2016. Approval is expected to be granted by 30 June 2016, at which point the Group will receive a variation payment of €6 million from commercial partner Recordati.

The full commercial launch of the product is currently anticipated to take place in the latter half of this year. Under the terms of the Group's licence agreement with Recordati, a payment of up €10 million in total is payable upon first commercial sales of PSD502® in France, Germany, Italy, Spain and Portugal, which comprises payments of €2 million in respect of each of these countries.

Jamie Gibson, CEO of Regent Pacific said, "We are pleased to be on track for the commercialization of PSD502®, and the anticipated variation approval will represent a vital and final step in the successful commercialisation of PSD502® in the EU, Russia, CIS and certain countries of North Africa. The Group will continue to work with Recordati on the process, and also focus on out-licensing in other major territories and on the submission for approval by the Food and Drug Administration within the US. We look forward to giving updates to the market on both fronts in the near term. "

PSD502® was approved by the EMA in November 2013. The approval process described in this announcement relates specifically to a reduced fill can version (not less than 12 dose/can). The Group's decision to reduce the fill size is intended to achieve an optimum price point per unit.

- END -

About Regent Pacific

Regent Pacific is a diversified investment group based in Hong Kong currently holding various corporate and strategic investments focusing on the healthcare and life sciences sectors. Its wholly-owned subsidiary, Plethora Solutions Holdings Plc, is a specialty pharmaceutical company whose core product PSD502® is the first EU approved topical prescription treatment for Premature Ejaculation, set to launch in EU in the latter half of 2016. The Group has a strong track record of investments and has returned US$298 million to shareholders in the 17.5 years of financial reporting since its IPO.

For further information, please contact:

Finsbury

James Hill
t : 3166 9888
e : james.hill@finsbury.com

Karen Yu
t : 3166 9866
e : Karen.yu@finsbury.com